tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncowebtumors-159Research ArticleСтатьиГенетическая гетерогенность меланомы кожи: новые мишени для селективного воздействияМазуренкоНаталья Николаевна

д.б.н., профессор, зав. лаборатории онкогеномики,

г. Москва

ФГБУ «Российский онкологический научный центр им. Н.Н.Блохина»Russian Federation20152111201504s238Copyright © Мазуренко Н.Н., 20152015Мазуренко Н.Н.Мазуренко Н.Н.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/159

В последнее время достигнуты значительные успехи в понимании молекулярных механизмов возникновения и развитии меланомы и наметился реальный прогресс в лечении пациентов с метастатической меланомой. Улучшение результатов послеоперационного лечения стало возможно благодаря блокаде основных сигнальных путей, специфичных для меланомы, с использованием молекулярно-нацеленных, таргетных, препаратов, ингибирующих продукты онкогенов.

ReferencesМазуренко Н. Н. Генетические особенности и маркеры меланомы кожи. Усп. мол. онкологии. 2014; 1(2): 27–36.Мазуренко Н. Н. Генетические особенности и маркеры меланомы кожи. Усп. мол. онкологии. 2014; 1(2): 27–36.Мазуренко Н. Н., И. В. Цыганова, А. А. Лушникова и др. Спектр мутаций онкогенов различается в субтипах меланомы кожи. Мол. биол. 2015; 49(6).Мазуренко Н. Н., И. В. Цыганова, А. А. Лушникова и др. Спектр мутаций онкогенов различается в субтипах меланомы кожи. Мол. биол. 2015; 49(6).Beadling C., Jacobson-Dunlop E., Hodi F. S., et al. KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 2008; 14(21): 6821–6828.Beadling C., Jacobson-Dunlop E., Hodi F. S., et al. KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 2008; 14(21): 6821–6828.Bello D. M., Ariyan C. E., Carvajal R. D. Melanoma mutagenesis and aberrant cell signaling. Cancer Control. 2013; 20(4): 261–281.Bello D. M., Ariyan C. E., Carvajal R. D. Melanoma mutagenesis and aberrant cell signaling. Cancer Control. 2013; 20(4): 261–281.Carvajal R. D., Sosman J. A., Quevedo J. F., et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014. 311(23). 2397–2405.Carvajal R. D., Sosman J. A., Quevedo J. F., et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014. 311(23). 2397–2405.Chakraborty R., Wieland C. N., Comfere N. I. Molecular targeted therapies in metastatic melanoma. Pharmacogen and Pers.Med. 2013; 6: 49–56.Chakraborty R., Wieland C. N., Comfere N. I. Molecular targeted therapies in metastatic melanoma. Pharmacogen and Pers.Med. 2013; 6: 49–56.Chapman P. B., Hauschild A., Robert C., et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011; 364(26): 2507–2516.Chapman P. B., Hauschild A., Robert C., et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011; 364(26): 2507–2516.Curtin J. A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 2005; 353: 2135–2147.Curtin J. A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 2005; 353: 2135–2147.Dahlman K. B., Xia J., Hutchinson K., et al. BRAF (L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2012; 2(9): 791–797.Dahlman K. B., Xia J., Hutchinson K., et al. BRAF (L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2012; 2(9): 791–797.Dai J., Kong Y., Si L., et al. Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib. Clin. Cancer Res. 2013; 19: 6935–6942.Dai J., Kong Y., Si L., et al. Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib. Clin. Cancer Res. 2013; 19: 6935–6942.Davies H., Bignell G. R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892): 949–954.Davies H., Bignell G. R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892): 949–954.Davies M. A. The role of the PI3K-AKT pathway in melanoma. Cancer J. 2012; 18:142–147.Davies M. A. The role of the PI3K-AKT pathway in melanoma. Cancer J. 2012; 18:142–147.Dumaz N. Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. Small GTPases. 2011; 2(5): 289–292.Dumaz N. Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. Small GTPases. 2011; 2(5): 289–292.Fecher L. A., Cummings S. D., Keefe M. J., Alani R. M. Towards a molecular classification of melanoma. J. Clin. Oncol. 2007; 25: 1606–1620.Fecher L. A., Cummings S. D., Keefe M. J., Alani R. M. Towards a molecular classification of melanoma. J. Clin. Oncol. 2007; 25: 1606–1620.Fedorenko I. V., Gibney G. T., Keiran S. M. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene. 2013; 32: 3009–3018.Fedorenko I. V., Gibney G. T., Keiran S. M. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene. 2013; 32: 3009–3018.Flaherty K. T., Infante J. R., Daud A., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012. 367(18). 1694–1703.Flaherty K. T., Infante J. R., Daud A., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012. 367(18). 1694–1703.Gaudi S., Messina J. L. Molecular Bases of Cutaneous and Uveal Melanomas. Pathol. Res. Int. 2011; Article ID159421, 1–8 pages.Gaudi S., Messina J. L. Molecular Bases of Cutaneous and Uveal Melanomas. Pathol. Res. Int. 2011; Article ID159421, 1–8 pages.Glitza IC, Davies MA. Genotyping of cutaneous melanoma. Chin. Clin. Oncol.. 2014p; 3(3): 27.Glitza IC, Davies MA. Genotyping of cutaneous melanoma. Chin. Clin. Oncol.. 2014p; 3(3): 27.Grimaldi AM, Simeone E, Festino L, et al. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway. Discov Med. 2015;19(107):455–61.Grimaldi AM, Simeone E, Festino L, et al. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway. Discov Med. 2015;19(107):455–61.Hansson J. Familial cutaneous melanoma. Adv. Exp. Med. Biol. 2010; 685: 134–145.Hansson J. Familial cutaneous melanoma. Adv. Exp. Med. Biol. 2010; 685: 134–145.Hauschild A., Grob J. J., Demidov L. V., et al. Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839): 358–365.Hauschild A., Grob J. J., Demidov L. V., et al. Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839): 358–365.Hayward N. K. Genetics of melanoma predisposition. Oncogene. 2003; 22(20): 3053–3062.Hayward N. K. Genetics of melanoma predisposition. Oncogene. 2003; 22(20): 3053–3062.Hodis E., Watson I. R., Kryukov G. V., et al. A landscape of driver mutations in melanoma. Cell. 2012; 150(2): 251–263.Hodis E., Watson I. R., Kryukov G. V., et al. A landscape of driver mutations in melanoma. Cell. 2012; 150(2): 251–263.Hutchinson K. E., Lipson D., Stephens P. J., et al. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin. Cancer Res. 2013. 19(24). 6696–6702.Hutchinson K. E., Lipson D., Stephens P. J., et al. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin. Cancer Res. 2013. 19(24). 6696–6702.Hutchinson K. E. Johnson DB, Johnson AS, et al., ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of drivernegativemelanoma. Oncotarget. 2015; 6(26): 22348–22360.Hutchinson K. E. Johnson DB, Johnson AS, et al., ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of drivernegativemelanoma. Oncotarget. 2015; 6(26): 22348–22360.Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010; 468(7326): 968–972.Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010; 468(7326): 968–972.Kelleher F. C., McArthur G. A. Targeting NRAS in melanoma. Cancer J. 2012; 18: 132–136.Kelleher F. C., McArthur G. A. Targeting NRAS in melanoma. Cancer J. 2012; 18: 132–136.Kirkwood J. M., Long G. V., Trefzer U., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13(11): 1087–1095.Kirkwood J. M., Long G. V., Trefzer U., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13(11): 1087–1095.Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: an open-label, multicentre, safety study Lancet Oncol. 2014; 15(4): 436–44.Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: an open-label, multicentre, safety study Lancet Oncol. 2014; 15(4): 436–44.Larkin J, Ascierto PA, Dreno B., et al. Combined vemurafenib and combimetinib in BRAF –mutated melanoma. N Engl J Med. 2014; 371(20):1867–76.Larkin J, Ascierto PA, Dreno B., et al. Combined vemurafenib and combimetinib in BRAF –mutated melanoma. N Engl J Med. 2014; 371(20):1867–76.Long G. V., Menzies A. M., Nagrial A. M., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 2011; 29(10):1239–4621.Long G. V., Menzies A. M., Nagrial A. M., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 2011; 29(10):1239–4621.Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014; 371(20):1877–88.Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014; 371(20):1877–88.МаcKie R.M., Hauschild A., Eggermont A. M. Epidemiology of invasive cutaneous melanoma. Ann. Oncol. 2009; 20, Suppl. 6. 1–7.МаcKie R.M., Hauschild A., Eggermont A. M. Epidemiology of invasive cutaneous melanoma. Ann. Oncol. 2009; 20, Suppl. 6. 1–7.Patel SP, Kim KB, Papadopoulos NE, et al. A phase II study of gefitinib in patients with metastatic melanoma.Melanoma Res. 2011; 21(4):357–363.Patel SP, Kim KB, Papadopoulos NE, et al. A phase II study of gefitinib in patients with metastatic melanoma.Melanoma Res. 2011; 21(4):357–363.Platz A., Egyhazi S., Ringborg U., Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol. 2008; 1(4): 395–405.Platz A., Egyhazi S., Ringborg U., Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol. 2008; 1(4): 395–405.Pleasance E. D., Cheetham R. K., Stephens P. J., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010. 463(7278). 191–196.Pleasance E. D., Cheetham R. K., Stephens P. J., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010. 463(7278). 191–196.Rajakulendran T., Sahmi M., Lefrançois M., et al. A dimerizationdependent mechanism drives RAF catalytic activation. Nature. 2009; 461(7263): 542–545.Rajakulendran T., Sahmi M., Lefrançois M., et al. A dimerizationdependent mechanism drives RAF catalytic activation. Nature. 2009; 461(7263): 542–545.Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013; 368(14):1365–1366.Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013; 368(14):1365–1366.Ribas A., Gonzalez R., Pavlick A., et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol 2014; 15(9):954–965.Ribas A., Gonzalez R., Pavlick A., et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol 2014; 15(9):954–965.Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372(1): 30–39.Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372(1): 30–39.Spagnolo F., Ghiorzo P, Orgiano L, et al., BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther. 2015; 8: 157–168.Spagnolo F., Ghiorzo P, Orgiano L, et al., BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther. 2015; 8: 157–168.Tschandl P., Berghoff A. S., Preusser M., et al. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. PLoS One. 2013; 8(7): e69639.Tschandl P., Berghoff A. S., Preusser M., et al. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. PLoS One. 2013; 8(7): e69639.Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014; 4(1): 94–109.Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014; 4(1): 94–109.Voskoboynik M., Arkenau H. T. Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence. Biochem. Res. Intern. 2014. Vol. 2014, Article ID307059, 9 pages.Voskoboynik M., Arkenau H. T. Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence. Biochem. Res. Intern. 2014. Vol. 2014, Article ID307059, 9 pages.Vredeveld L. C., Possik P. A., Smit M. A., et al. Abrogation of BRAF V600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012; 6: 1055–1069.Vredeveld L. C., Possik P. A., Smit M. A., et al. Abrogation of BRAF V600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012; 6: 1055–1069.Wolchok J. D., Kluger H., Callahan M. K., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013; 369(2): 122–133.Wolchok J. D., Kluger H., Callahan M. K., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013; 369(2): 122–133.Xia J, Jia P., Hutchinson K. E., et al. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol. Cancer Ther. 2014; 13(7): 1918–1928.Xia J, Jia P., Hutchinson K. E., et al. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol. Cancer Ther. 2014; 13(7): 1918–1928.

The authors declare that there are no conflicts of interest present.